Intrials Selects Medidata to Solve Trial Complexity and Gain Competitive Edge

New York – June 28, 2023 – Medidata, a Dassault Systèmes company, is enabling Intrials, a Latin American contract research organization (CRO), to expand its business with Medidata’s Rave CTMS, Rave eTMF, and Rave Site Payments. The agreement, which includes training and support from Medidata Professional Services, helps Intrials advance its offerings in Latin America with the capability to manage more complex trials and attract larger global clients.

“The technology from Medidata drives our success in bringing new clinical studies to Latin America by automating our workflow and streamlining manual processes,” said Sergio Braga Filho, president of Intrials. “This is a tremendous opportunity to make our region a showcase for clinical research and the development of therapies to benefit patients.”

Medidata technology will provide Intrials with a collaborative platform for creating and managing trial content, offer near real-time views of trial status, and help the CRO complete trials on time and on budget. 

Intrials specializes in recruitment and clinical research across Latin America, with offices in Brazil, Chile, Peru, Colombia, Mexico, and Argentina. For nearly 25 years they have worked with global researchers to conduct trials, lead vaccine efficacy research, and support studies on multiple rare diseases. 

“As our sponsors extend their studies in emerging markets in Latin America, they now have a Medidata CRO partner with a growing presence in the region with the same platform they rely on around the world,” said Joan Shaiman, senior vice president Partners at Medidata. “Our solutions give Intrials a competitive advantage, with efficiencies in trial enrollment, site payments, and trial start-up to serve their customers and bring drugs to market faster.”

Following its successful implementation of Medidata’s trial technology, Intrials will earn Rave EDC certification to further expand its offerings. Once certified, the Intrials team will enjoy greater efficiencies when using Medidata products and services in support of their goals to bring speed and accuracy to clinical trials.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.